Johannes Levin
Johannes Levin
Professor for Clinical Neurodegeneration, Ludwig-Maximilians-Universität München; CMO MODAG GmbH
Verified email at
Cited by
Cited by
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
GU Höglinger, G Respondek, M Stamelou, C Kurz, KA Josephs, AE Lang, ...
Movement disorders 32 (6), 853-864, 2017
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease
O Preische, SA Schultz, A Apel, J Kuhle, SA Kaeser, C Barro, S Gräber, ...
Nature medicine 25 (2), 277-283, 2019
Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study
BA Gordon, TM Blazey, Y Su, A Hari-Raj, A Dincer, S Flores, ...
The Lancet Neurology 17 (3), 241-250, 2018
Hough-CNN: Deep learning for segmentation of deep brain regions in MRI and ultrasound
F Milletari, SA Ahmadi, C Kroll, A Plate, V Rozanski, J Maiostre, J Levin, ...
Computer Vision and Image Understanding 164, 92-102, 2017
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease
NR Barthélemy, Y Li, N Joseph-Mathurin, BA Gordon, J Hassenstab, ...
Nature medicine 26 (3), 398-407, 2020
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease
J Wagner, S Ryazanov, A Leonov, J Levin, S Shi, F Schmidt, C Prix, ...
Acta neuropathologica 125, 795-813, 2013
Inhibition and disaggregation of α-synuclein oligomers by natural polyphenolic compounds
M Caruana, T Högen, J Levin, A Hillmer, A Giese, N Vassallo
FEBS letters 585 (8), 1113-1120, 2011
Single particle characterization of iron-induced pore-forming α-synuclein oligomers
M Kostka, T Hogen, KM Danzer, J Levin, M Habeck, A Wirth, R Wagner, ...
Journal of Biological Chemistry 283 (16), 10992-11003, 2008
The differential diagnosis and treatment of atypical parkinsonism
J Levin, A Kurz, T Arzberger, A Giese, GU Höglinger
Deutsches Ärzteblatt International 113 (5), 61, 2016
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
E McDade, G Wang, BA Gordon, J Hassenstab, TLS Benzinger, V Buckles, ...
Neurology 91 (14), e1295-e1306, 2018
Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury
M Suárez-Calvet, MÁ Araque Caballero, G Kleinberger, RJ Bateman, ...
Science translational medicine 8 (369), 369ra178-369ra178, 2016
Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study
KM Moore, J Nicholas, M Grossman, CT McMillan, DJ Irwin, L Massimo, ...
The Lancet Neurology 19 (2), 145-156, 2020
Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology
M Suárez-Calvet, E Morenas-Rodríguez, G Kleinberger, K Schlepckow, ...
Molecular neurodegeneration 14, 1-14, 2019
Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation
M Kunadt, K Eckermann, A Stuendl, J Gong, B Russo, K Strauss, S Rai, ...
Acta neuropathologica 129, 695-713, 2015
First symptom in sporadic Creutzfeldt–Jakob disease
GD Rabinovici, PN Wang, J Levin, L Cook, M Pravdin, J Davis, ...
Neurology 66 (2), 286-287, 2006
Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy
M Brendel, H Barthel, T van Eimeren, K Marek, L Beyer, M Song, C Palleis, ...
JAMA neurology 77 (11), 1408-1419, 2020
Four-repeat tauopathies
TW Roesler, AT Marvian, M Brendel, NP Nykaenen, M Hoellerhage, ...
Progress in neurobiology 180, 101644, 2019
Which ante mortem clinical features predict progressive supranuclear palsy pathology?
G Respondek, C Kurz, T Arzberger, Y Compta, E Englund, LW Ferguson, ...
Movement Disorders 32 (7), 995-1005, 2017
Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study
EL van der Ende, LH Meeter, JM Poos, JL Panman, LC Jiskoot, ...
The Lancet Neurology 18 (12), 1103-1111, 2019
Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial …
E Lhommée, L Wojtecki, V Czernecki, K Witt, F Maier, L Tonder, ...
The Lancet Neurology 17 (3), 223-231, 2018
The system can't perform the operation now. Try again later.
Articles 1–20